Cargando…
Prevention of atherosclerosis in patients living with HIV
INVESTIGATIONAL PRODUCT: Rosuvastatin (Crestor(®); Astra Zeneca). ACTIVE INGREDIENTS: Rosuvastatin (5 mg). STUDY TITLE: Prevention of Atherosclerosis in Patients Living with HIV. PHASE OF STUDY: Phase III. AIMS: To assess whether rosuvastatin therapy could slow the progression of the carotid intima-...
Autores principales: | De Lorenzo, Ferruccio, Boffito, Marta, Collot-Teixeira, Sophie, Gazzard, Brian, McGregor, John L, Shotliff, Kevin, Xiao, Han |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2672452/ https://www.ncbi.nlm.nih.gov/pubmed/19436663 |
Ejemplares similares
-
Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease
por: Nadinskaia, Maria, et al.
Publicado: (2021) -
Short Communication: Reduced Nevirapine Concentrations Among HIV-Positive Women Receiving Mefloquine for Intermittent Preventive Treatment for Malaria Control During Pregnancy
por: Haaland, Richard E., et al.
Publicado: (2018) -
Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients
por: Zhang, Jianping, et al.
Publicado: (2015) -
A randomized, placebo-controlled trial of patient education for acute low back pain (PREVENT Trial): statistical analysis plan
por: Traeger, Adrian C., et al.
Publicado: (2017) -
Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment
por: Weller, Stephen, et al.
Publicado: (2013)